<DOC>
	<DOCNO>NCT00738374</DOCNO>
	<brief_summary>This single arm study ass efficacy safety MabThera + chlorambucil induction therapy , follow responder maintenance therapy observation elderly patient previously untreated chronic lymphocytic leukemia . During induction phase patient receive 2 x 4 weekly course chlorambucil follow 8 x 4 weekly course chlorambucil + MabThera . Subsequently , responder randomize receive 12 dos MabThera give every 8 week , treatment . The anticipated time study treatment 2+ year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Plus Chlorambucil Patients With Previously Untreated Chronic Lymphocytic Leukemia .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>adult patient , &gt; =60 year age ; CD20+ chronic lymphocytic leukemia ( CLL ) ; previous treatment CLL ; ECOG performance status 01. comorbid condition require long term use systemic corticosteroid study treatment ; history severe cardiac disease ; transformation aggressive Bcell malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>